NFE2L2 and cancer: We used the MSK MetTropism cohort to evaluate the molecular characteristics of NFE2L2 MU across pan-cancers, and found that 1.9% of patients (n = 487) had at least one NFE2L2 MU (Fig. 3A and Additional file 1: Fig. S3A).